{"id":900682,"date":"2025-10-27T16:04:22","date_gmt":"2025-10-27T20:04:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"modified":"2025-10-27T16:04:22","modified_gmt":"2025-10-27T20:04:22","slug":"coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","title":{"rendered":"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares"},"content":{"rendered":"

<\/p>\n

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares<\/b><\/p>\n

HOUSTON–(BUSINESS WIRE<\/a>)–
\nCoya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced the closing of its $23.0 million underwritten public offering of 4,181,818 shares of its common stock, including 545,454 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its option to purchase additional shares of common stock in the public offering. The public offering price, before underwriting discounts and commissions, for each share of common stock was $5.50. All of the securities in the underwritten public offering were sold by the Company. Investors in the offering included existing investors and new biotechnology and healthcare-focused institutional investors.<\/p>\n

\nLucid Capital Markets acted as sole book-running manager for the public offering. Allele Capital Partners, LLC, through its executing broker-dealer, Wilmington Capital Securities, LLC, acted as financial advisor to the Company.<\/p>\n

\nThe gross proceeds to the Company from the public offering were approximately $23.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the public offering for working capital and general corporate purposes, including funding its clinical development plan.<\/p>\n

\nThe common stock described above was offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-289511), including a base prospectus, previously filed with and subsequently declared effective by the Securities and Exchange Commission (the \u201cSEC\u201d) on August 19, 2025. A preliminary prospectus supplement and the accompanying base prospectus relating to the public offering has been filed with the SEC and is available on the SEC\u2019s website at http:\/\/www.sec.gov<\/a>. A final prospectus supplement and the accompanying base prospectus describing the terms of the public offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus relating to this public offering may be obtained at the SEC\u2019s website at http:\/\/www.sec.gov<\/a> or by request from Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th<\/sup> Floor, New York, NY 10022.<\/p>\n

\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n

About Coya Therapeutics, Inc.<\/b><\/p>\n

\nHeadquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (\u201cTregs\u201d) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.<\/p>\n

\nCoya\u2019s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya\u2019s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.<\/p>\n

\nFor more information about Coya, please visit www.coyatherapeutics.com<\/a>.<\/p>\n

About COYA 302<\/b><\/p>\n

\nCOYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS. These mechanisms may have additive or synergistic effects.<\/p>\n

\nCoya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov<\/a> Identifier: NCT 07161999).<\/p>\n

\nCOYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Coya\u2019s expectations on the anticipated use of proceeds from the public offering. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed under the caption \u201cRisk Factors\u201d in the final prospectus supplement related to the public offering will be filed with the SEC, the Company\u2019s most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements speak only as of the date hereof. Coya does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251027959114\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n<\/b>
David Snyder, CFO
\n
david@coyatherapeutics.com<\/a><\/p>\n

astr partners
\n<\/b>
Matthew Beck
\n
matthew.beck@astrpartners.com
\n<\/a>
917-415-1750<\/p>\n

Media Contacts
\n<\/b>
Russo Partners
\n<\/i><\/b>
Olipriya Das
\n
Olipriya.Das@russopartnersllc.com
\n<\/a>
646-942-5588<\/p>\n

\nMatthew Purcell
\n
matthew.purcell@russopartnersllc.com
\n<\/a>
646-942-5595<\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Finance Neurology Public Relations\/Investor Relations Genetics Communications Clinical Trials Professional Services Biotechnology Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares HOUSTON–(BUSINESS WIRE)– Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced the closing of its $23.0 million underwritten public offering of 4,181,818 shares of its common stock, including 545,454 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its option to purchase additional shares of common stock in the public offering. The public offering price, before underwriting discounts and commissions, for each share of common stock was $5.50. … <\/p>\n

Continue reading “Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-900682","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCoya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares HOUSTON–(BUSINESS WIRE)– Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced the closing of its $23.0 million underwritten public offering of 4,181,818 shares of its common stock, including 545,454 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its option to purchase additional shares of common stock in the public offering. The public offering price, before underwriting discounts and commissions, for each share of common stock was $5.50. … Continue reading "Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T20:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares\",\"datePublished\":\"2025-10-27T20:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"wordCount\":924,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"name\":\"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-10-27T20:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_locale":"en_US","og_type":"article","og_title":"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk","og_description":"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares HOUSTON–(BUSINESS WIRE)– Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced the closing of its $23.0 million underwritten public offering of 4,181,818 shares of its common stock, including 545,454 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its option to purchase additional shares of common stock in the public offering. The public offering price, before underwriting discounts and commissions, for each share of common stock was $5.50. … Continue reading \"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-27T20:04:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares","datePublished":"2025-10-27T20:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"wordCount":924,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","name":"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-10-27T20:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251027959114r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-announces-closing-of-23-0-million-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=900682"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900682\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=900682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=900682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=900682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}